Insulin resistance levels chart for accurate tracking

Key Takeaways

An insulin resistance levels chart gives clinicians quick reference thresholds for HOMA-IR, fasting insulin, and fasting glucose to stratify metabolic risk.

HOMA-IR below 1.0 indicates normal insulin sensitivity, 1.0-1.9 is borderline, 2.0-2.9 suggests insulin resistance, and 3.0 or higher indicates severe resistance.

Female-specific HOMA-IR cut-offs differ from male cohort data. PCOS amplifies insulin resistance and requires contextual interpretation alongside clinical presentation.

Pabau’s digital forms and client records help clinicians document metabolic panel results, track trends, and link lab findings directly to patient consultations.

Clinicians assessing metabolic health often juggle multiple reference ranges across different lab reports. An insulin resistance levels chart centralizes the key diagnostic thresholds in one visual resource, enabling faster patient risk stratification and clearer documentation of metabolic findings during consultations.

This guide explains how to use the chart, what each marker means, and why female-specific guidance matters when interpreting insulin resistance in PCOS and other populations.

What is an insulin resistance levels chart?

An insulin resistance levels chart is a clinical reference tool that displays diagnostic thresholds for biomarkers used to assess and stage insulin resistance.

It helps practitioners quickly categorize fasting insulin, HOMA-IR scores, fasting glucose, HbA1c, and metabolic panel markers into normal, borderline, and pathological ranges.

Insulin resistance develops when cells become progressively less responsive to circulating insulin, forcing the pancreas to secrete more insulin to maintain glucose homeostasis.

Untreated, this compensatory hyperinsulinemia can progress to prediabetes, type 2 diabetes, and metabolic syndrome. Early detection via the chart enables timely lifestyle and pharmacological intervention.

The HOMA-IR ranges in this chart come from peer-reviewed endocrinology literature and standard clinical practice. Neither the Endocrine Society nor the American Diabetes Association (ADA) publishes an official HOMA-IR cut-off.

The ADA’s own diagnostic criteria for prediabetes and diabetes are based on fasting glucose, HbA1c, and oral glucose tolerance testing, while the Endocrine Society’s guidelines address related metabolic conditions.

This chart serves as both a patient education tool and a clinician-facing documentation framework for metabolic health EMR workflows.

How to use this chart in practice

1. Order a fasting metabolic panel. Instruct the patient to fast 10-12 hours overnight. Request fasting insulin, fasting glucose, lipid panel (triglycerides, HDL), and HbA1c. Ensure the lab reports values in the units used in this guide (μIU/mL for insulin, mg/dL for glucose).
2. Calculate HOMA-IR. Use the formula: fasting insulin (μIU/mL) × fasting glucose (mg/dL) ÷ 405, then record the result in the patient’s chart using this staging: below 1.0 indicates normal sensitivity, 1.0-1.9 is borderline, 2.0-2.9 is insulin resistant, and 3.0 or higher is severely resistant.
3. Cross-reference fasting glucose. If fasting glucose is 100-125 mg/dL, the patient meets ADA criteria for prediabetes. If ≥126 mg/dL on repeat testing, diabetes diagnosis is confirmed. Document this alongside the HOMA-IR result.
4. Review HbA1c and triglycerides. A1c below 5.7% indicates normal glucose control, 5.7-6.4% indicates prediabetes, and 6.5% or higher indicates diabetes. Elevated triglycerides (>150 mg/dL) co-occur with insulin resistance and metabolic syndrome. Record both values for a holistic metabolic snapshot.
5. Document results in your patient record. Use digital forms to capture the panel results and HOMA-IR calculation directly in the patient’s clinical record. Fill in the downloadable template’s interpretation, clinical insights, and dietary recommendation fields, and use its progress-tracking sections to follow the patient across return visits.

This structured workflow transforms scattered lab values into a clinician-friendly snapshot that informs diagnosis, risk stratification, and follow-up planning.

Core reference ranges: Understanding the thresholds

The chart organizes four primary markers into graduated ranges. Each has clinical significance for assessing metabolic health and guiding intervention.

Note on laboratory variation: Reference ranges vary by assay and laboratory. Always use your lab’s reference intervals for fasting insulin and glucose. These ranges represent typical clinical cut-offs but should be contextualized with the patient’s clinical presentation and symptoms.

The fasting insulin range printed on the downloadable template is illustrative, not a universal standard. Replace it with your ordering lab’s own reference interval before using the template with patients.

Diagnostic methods: Which test should you order?

Several approaches exist to assess insulin resistance. The chart supports multiple testing strategies depending on clinical context and available resources.

• HOMA-IR (Homeostatic Model Assessment): Calculated from fasting insulin and glucose. A research-grade screening tool widely used in clinical practice. Inexpensive but less accurate than direct insulin secretion/sensitivity measurement. Best for population screening and trend monitoring.
• Fasting Insulin Alone: Direct marker of basal pancreatic compensation. Elevated levels (>12 μIU/mL) suggest compensatory hyperinsulinemia even when glucose is normal. Simple, interpretable, but does not account for glucose response.
• Oral Glucose Tolerance Test (OGTT): Gold standard for glucose tolerance assessment. Captures dynamic insulin response to a 75 g glucose load over 2 hours. More labor-intensive but clinically definitive for prediabetes/diabetes diagnosis.
• HbA1c: Reflects average glucose over 3 months. Less sensitive for detecting early insulin resistance but reliable for diabetes staging. Does not directly measure insulin levels.

Most practitioners use a combination: fasting insulin + fasting glucose to calculate HOMA-IR, plus HbA1c for long-term glucose control and client record documentation of metabolic trends.

Interpreting key metabolic markers alongside insulin resistance

Insulin resistance rarely appears in isolation. The chart includes supporting metabolic panel markers that refine risk stratification and guide clinical decision-making.

Triglycerides. Fasting triglycerides >150 mg/dL are a hallmark of insulin resistance and metabolic syndrome. Elevated triglycerides reflect impaired lipid metabolism secondary to compensatory hyperinsulinemia. Plot alongside HOMA-IR to confirm the metabolic picture.

HDL cholesterol. Insulin-resistant patients often have low HDL (<40 mg/dL in men, <50 mg/dL in women). The triglyceride-to-HDL ratio (normal <2) is a simple surrogate for insulin resistance severity. High triglycerides + low HDL = heightened cardiometabolic risk.

Blood pressure and waist circumference. Abdominal obesity and hypertension co-cluster with insulin resistance as features of metabolic syndrome. Document these anthropometric measures on the chart alongside lab values for a complete metabolic assessment.

Insulin resistance in women: PCOS and female-specific considerations

Standard HOMA-IR cut-offs (developed in large European cohorts, predominantly male or mixed-gender) may not translate directly to female populations or PCOS. Clinicians must contextualize thresholds with patient phenotype and reproductive history.

PCOS and insulin resistance. Up to 70% of women with PCOS have insulin resistance, independent of BMI. The disorder amplifies compensatory hyperinsulinemia, driving androgen excess and anovulation. In PCOS cohorts, HOMA-IR thresholds as low as 1.5-2.0 (compared to population averages of 1.0-2.0) may trigger intervention.

A woman with PCOS, HOMA-IR 1.8, and regular ovulatory cycles may have different cardiometabolic risk than a non-PCOS woman with identical HOMA-IR and absent menstrual regularity.

Reproductive health context. Elevated androgen levels in PCOS exacerbate insulin resistance. Insulin resistance, in turn, worsens androgen synthesis. Use the chart as a screening tool, then refine interpretation with functional medicine assessment of cycle regularity, hirsutism, acne, and baseline androgen levels (free testosterone, androstenedione).

Practice operations: Integrating the chart into patient documentation

The chart’s value multiplies when embedded into your practice’s documented workflow. Print a copy for each metabolic health consultation, or complete it digitally as part of the patient’s measurements-tracking workflow to flag abnormal values automatically.

Use the chart during consultations to educate patients about their results, clarify the relationship between fasting insulin elevation and glucose dysregulation, and frame lifestyle interventions (dietary modification, resistance training, sleep optimization) as first-line treatment before or alongside medication.

Document the completed chart in your patient record for historical reference and longitudinal trend assessment.

Ready to streamline metabolic health documentation?

Pabau's patient records, digital forms, and measurement tracking make it easy to document insulin resistance assessments, track lab trends, and link findings directly to clinical notes, so you can focus on patient outcomes, not paperwork.

Book a demo

Who is this chart for?

This chart serves multiple healthcare settings where metabolic assessment is core to diagnosis and management.

• Functional and integrative medicine practitioners: Managing metabolic health, insulin resistance reversal, and preventive metabolic screening in wellness-oriented practices.
• Metabolic health and longevity practices: Assessing insulin resistance as a driver of aging and cardiometabolic disease. Use the chart to stratify and monitor patient risk.
• Weight loss and obesity management programs: Establishing baseline insulin resistance to guide pharmacological (GLP-1 agonists, metformin) and lifestyle interventions.
• Endocrinologists and diabetes specialists: Confirming prediabetes and diabetes diagnoses and monitoring treatment response to lifestyle changes and medication.
• Women’s health and reproductive medicine: Evaluating PCOS, infertility, and menstrual disorders linked to insulin resistance, and contextualizing androgen screening within metabolic assessment.

Benefits of using this chart

Standardized reference ranges. A unified chart eliminates confusion from conflicting lab reports and non-standardized verbal reporting. Every consultation uses the same thresholds, improving consistency and patient trust.

Faster risk stratification. Within seconds, practitioners can place a patient into a risk category (normal, borderline, resistant, severely resistant) and frame the clinical message accordingly. No need to mental-math or consult external guidelines mid-consultation.

Enhanced patient education. Showing a patient their results on a clear visual chart makes the concept of insulin resistance concrete. Patients understand why an elevated HOMA-IR matters and why early intervention is worthwhile.

Documented clinical reasoning. Completed charts become part of the medical record, providing audit-trail evidence of systematic metabolic assessment. Useful for HIPAA compliance, insurance documentation, and continuity of care during referrals.

Conclusion

An insulin resistance levels chart centralizes the diagnostic thresholds clinicians need to assess metabolic health quickly and accurately during patient consultations. The chart transforms scattered lab values into a unified metabolic snapshot, enabling faster risk stratification and clearer patient education about the importance of early intervention.

Whether you manage metabolic health, oversee weight loss programs, or specialize in women’s reproductive health, this chart is a practical tool for every consultation. Download it, print it, and pair it with AI clinical documentation to standardize care and improve outcomes.

Book a demo to see how Pabau turns tools like this into a connected workflow across your whole practice.

Continue your research

Managing PCOS in your practice? Our PCOS hormone levels template gives you a ready-made framework to document androgen and reproductive hormone panels alongside insulin resistance markers.

Want a printable option for glucose tracking? Our blood sugar chart gives patients a simple take-home tool to log fasting and post-meal readings between visits.

Weighing lifestyle changes against medication? This clinical guide compares lifestyle and pharmacologic interventions for managing metabolic health.

Frequently asked questions